This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

12 Dec 2018

Cambrex expands analytical capabilities

The $1 million investment will assist in getting new products to commercial launch faster.

Cambrex is investing $1 million at its High Point, NC site to fit out 1,300 sq ft of analytical laboratory space and plans to hire nine chemical research and development scientists, as well as six analytical research and development scientists pursuant to this project. This investment follows the new $3.2 million, 11,000 sq ft analytical laboratory, completed in April 2018.

The expansion and fit out, which will include the installation of an additional 10 ultra-performance liquid chromatography (UPLC) instruments, is set to be completed by year-end 2018.

“Cambrex is seeing a significant increase in new projects, resulting in increased demand for analytical development capabilities within the Cambrex organization,” commented Brian Swierenga, VP, Operations and Site Director for Cambrex High Point. He added: “This further expansion will not only increase Cambrex’s internal analytical capabilities and capacity, but will assist in getting new products to commercial launch faster.”

At the facility, Cambrex produces complex APIs and intermediates requiring multi-step synthetic processes in batch sizes from milligrams to 100 kg to support clinical trials from Phase I to Phase III. The site is licensed with the US Drug Enforcement Administration (DEA) to manufacture Schedule II to Schedule V controlled substances. The acquisition enhanced Cambrex’s portfolio of small molecule API services and complements its large-scale, multi-purpose manufacturing facilities in the US and Europe.

This latest expansion at the 35,000-sq ft facility brings the investment at the site to over $9 million since the acquisition of PhamaCore by Cambrex in 2016.

Related News